Brazil vs Kazakhstan: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Kazakhstan
3,398 constant 2022 US$
in 2023
Brazil rank
10th
Kazakhstan rank
13th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Kazakhstan
How they compare
Brazil currently reports 4,102 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan, a difference of 704 constant 2022 US$.
That makes Brazil's figure about 1.2 times Kazakhstan's.
The two have swapped places 3 times across 7 shared years of data; in 2017 it was Kazakhstan ahead.
Brazil ranks 10th and Kazakhstan ranks 13th of 92 countries.
Across the 2 decades both report, Brazil averaged higher in 1 and Kazakhstan in 1.
Head to head by decade
| Decade | Brazil | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,620 constant 2022 US$ | 3,280 constant 2022 US$ | 659.67 constant 2022 US$ | Kazakhstan |
| 2020s | 3,988 constant 2022 US$ | 2,932 constant 2022 US$ | 1,056 constant 2022 US$ | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Kazakhstan?
- Brazil, at 4,102 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Kazakhstan?
- 704 constant 2022 US$, with Brazil ahead.
- How many years of comparable data are there for Brazil and Kazakhstan?
- 7 years are reported by both, from 2017 to 2023.
- How do Brazil and Kazakhstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Kazakhstan ranks 13th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.